<DOC>
	<DOC>NCT01455610</DOC>
	<brief_summary>The purpose of this multicenter and double-blind clinical trial is to prospectively assess the sensitivity, specificity, negative predictive value, positive predictive value, and accuracy in respectability of pancreatic head cancer with contrasted-enhanced MDCT and its various post processing techniques, taking operational and pathological records as the gold standard.</brief_summary>
	<brief_title>Resectability of Pancreatic Head Cancer by Contrast-enhanced MDCT:a Multi-center Study</brief_title>
	<detailed_description />
	<mesh_term>Adenocarcinoma</mesh_term>
	<mesh_term>Head and Neck Neoplasms</mesh_term>
	<criteria>Patients with (or suspected) pancreatic head cancer Being examined by contrastedenhanced MDCT Receiving surgical treatment (including palliative surgery) in all research centers Patients having (or suspected) pregnancy or breastfeeding Patients having allergic reactions to iodinated contrast agents or Hypersensitivity reactions to allergens(including drugs) Patients receiving ERCP before contrastedenhanced MDCT examination Patients without surgery because of a high degree of surgical risk</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2011</verification_date>
	<keyword>Computed tomography</keyword>
	<keyword>Contrast enhancement</keyword>
	<keyword>Pancreas</keyword>
	<keyword>Cancer</keyword>
	<keyword>Resectability</keyword>
</DOC>